Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute

Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical results in Nature Communications demonstrating the anti-cancer potential of ALRN-6924 in models of T-cell lymphoma (TCL).

As quoted in the press release:

Avivagen intends to use the proceeds to build-up inventory for anticipated revenue growth, and fund regulatory applications in new jurisdictions. The credit facility was originally entered into in 2015 and is for a total of CAD $1.8 million, of which Avivagen is now fully drawn. Under the terms of the credit facility, the Corporation had until the end of May 2018 to fully access this facility, and therefore decided to draw down the remaining balance. Interest accrues on the outstanding balance at 12% annually, of which 7% per annum is payable each quarter and 5% per annum is payable on maturity of the loan. The loan matures on November 13, 2019, at which time the full principal and the 5% accrued interest is payable. 500,000 warrants were issued in 2015 in consideration for the facility, which are now fully vested.

Click here to read the full press release.